United States Anti Depression Drugs Market 2025 | Industry Developments, Future Growth, Share & Industry Insights

Anti Depression Drugs Market reached US$ 15.81 billion in 2023 and is expected to reach US$ 22.10 billion by 2031, growing at a CAGR of 4.3% during the forecast period 2024-2031.

DataM Intelligence unveils its latest report on the "Anti Depression Drugs Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging opportunities that can guide businesses in seizing growth potential and crafting winning strategies. Packed with data-driven insights on current developments and future trends, this report is essential for companies aiming to stay ahead in the competitive Market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/anti-depression-drugs-market?sg

List of Top Key Player: Eli Lilly and Company, Viatris Inc., GlaxoSmithKline Plc., Zheijiang Huahai Pharmaceutical Co. Ltd., AstraZeneca Plc., Takeda Pharmaceutical Co. Ltd, Pfizer Inc., Aurobindo Pharma Limited, H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd.

United States - Industry Developments:

✅ FDA Expands Spravato Approval - In January 2025, the FDA approved Spravato (esketamine) nasal spray as a standalone treatment for major depressive disorder, previously requiring adjunctive oral antidepressants.

✅ AbbVie Acquires Gilgamesh's Bretisilocin - On August 25, 2025, AbbVie announced the acquisition of Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin, for the treatment of major depressive disorder.

✅ FDA Approves Gepirone Hydrochloride ER - In September 2025, the FDA approved gepirone hydrochloride extended-release tablets for the treatment of major depressive disorder.

Japan - Industry Developments:

✅ Viatris Files SNDA for Effexor® - On April 21, 2025, Viatris submitted a supplemental new drug application to Japan's Ministry of Health, Labor and Welfare for the approval of Effexor® for the treatment of generalized anxiety disorder.

✅ PMDA Accelerates Drug Review - In 2025, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) implemented measures to expedite drug development and address the challenge of "Drug Loss," aiming to provide innovative drugs to patients more efficiently.

South Korea - Industry Developments:

✅ UZEDY® Approved for Schizophrenia - On September 10, 2025, Medincell announced that UZEDY® was approved in South Korea for the treatment of schizophrenia, expanding its availability following its U.S. launch in 2023.

Europe - Industry Developments:

✅ Zurzuvae Approved in EU - On September 17, 2025, the European Medicines Agency granted marketing authorization for Zurzuvae, the first oral medication specifically designed for postpartum depression, valid throughout the EU.

✅ Rejoyn® Launched in Great Britain - On June 17, 2025, Otsuka Pharmaceutical and Click Therapeutics announced the launch of Rejoyn®, a prescription smartphone app developed as a treatment for depressive disorder, in Great Britain.

✅ European Citizens' Initiative for Psychedelic-Assisted Therapies - Launched in early 2025, the European Citizens' Initiative aims to collect one million signatures to urge the European Commission to take action on psychedelic-assisted therapies.

Forecast Projection:

The Global Anti Depression Drugs Market is poised for significant growth between 2025 and 2032. In 2024, the market maintained a steady upward trajectory, and with strategic initiatives by leading players accelerating adoption, the market is expected to soar throughout the forecast period. Companies leveraging these trends are well-positioned to capture emerging opportunities and maximize revenue potential.

Market Intelligence Research Process:

The Anti Depression Drugs Market research report by DataM Intelligence combines primary and secondary data to deliver deep, actionable insights. It examines the full spectrum of factors shaping the industry, from government regulations and market conditions to competitive dynamics, historical trends, technological breakthroughs, upcoming innovations, and potential challenges. This comprehensive analysis not only highlights growth prospects but also identifies barriers, equipping businesses to navigate market volatility and capitalize on emerging opportunities.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=anti-depression-drugs-market?sg

Key Segmentation:

By Drug Class (Selective Serotonin Reuptake Inhibitors (SSRIs), Monoamine Oxidase Inhibitors (MAOIs), Norepinephrine-dopamine Reuptake Inhibitor, Serotonin-norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Serotonin Modulators, Others)

By Depression Disorder (Major Depressive Disorder, Bipolar depression, Obsessive-compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder , Others)

By Route of Administration (Oral, Parenteral, Others)

By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Global Growth Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1 - Market Overview: Kickstarts the report with a comprehensive snapshot of the Anti Depression Drugs Market, summarizing key segments by region, product type, and application. Highlights include market size, segment growth potential, and short- & long-term industry outlook.

Chapter 2 - Emerging Trends: Uncovers the game-changing trends and high-impact innovations shaping the future of the industry.

Chapter 3 - Competitive Landscape: Offers a deep dive into market competition, detailing revenue shares, strategic initiatives, and recent mergers & acquisitions.

Chapter 4 - Top Player Profiles: Features detailed company profiles, covering revenue, profit margins, product lines, and major milestones for leading market players.

Chapters 5 & 6 - Regional & Country Analysis: Breaks down revenue performance across global regions, providing insights on market sizes, opportunities, and growth prospects worldwide.

Chapter 7 - Segmentation Analysis: Explores market segmentation by type, revealing high-potential categories and guiding businesses towards lucrative areas.

Chapter 8 - Application Insights: Examines downstream markets and identifies promising sectors for expansion, showing how different applications are driving growth.

Chapter 9 - Supply Chain Mapping: Maps the entire industry supply chain, highlighting upstream and downstream activities for a holistic market perspective.

Chapter 10 - Key Takeaways: Concludes with critical insights and actionable strategies, equipping stakeholders to make informed decisions and stay ahead in the market.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/anti-depression-drugs-market?sg

FAQ's

Q1: What is the current size of the Anti Depression Drugs Market and its future potential?

A: The Anti Depression Drugs Market was valued at US$ 15.81 billion in 2023 and is projected to surge to US$ 22.10 billion by 2031

Q2: How fast is the Anti Depression Drugs Market expected to grow in the coming years?

A: The market is forecast to expand at a robust CAGR of 4.3% between 2024-2031, signaling strong global growth and investment potential.

Q3: Which regions are dominating the Anti Depression Drugs Market and which are fastest-growing?

A: North America is expected to hold a significant position in the anti-depression drugs market share.

Request 2 Days Free Trials with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sg

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.